Stem cell exosomes are small vesicles ranging from 30-100nm in size that are secreted by all stem cell types. They facilitate a range of important cellular functions. As the market for stem cell exosomes has emerged, a number of investment groups have made bets on this rapidly growing marketplace. [Read more…]
Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research
Kyoto University has announced that it will start providing human embryonic stem cells (ES cells) by July 2018 to universities and companies within Japan for clinical trial applications. This is a world-first, as most countries have been hesitant to support wide-spread production and distribution of this controversial cell type.
Previously Japan limited the use of human embryonic stem cells to basic research, because the cells are produced from human embryos, making them a highly controversial cell type. In 2014, the Japanese government revised it guidelines, making possible the use human ES cells in clinical studies, as well as laboratory research. [Read more…]
Evolution of the Cord Blood Banking Market – Transplant Medicine to RM to Longevity
Cord blood banking initially emerged as a commercial service in the late 1980’s and early 1990’s, because of potential applications related to Transplant Medicine. While an effective therapeutic approach, this unfortunately produced low utilization rates for stored cord blood units.
As a result, Regenerative Medicine (RM) applications of cord blood emerged over time, expanding approved used for cord blood to approximately 80 total. Exciting regenerative medicine applications for umbilical cord blood include its potential to treat neurological conditions, such as cerebral palsy (CP) and autism. These applications are being researched by one of the luminaries in the field, Dr. Joanne Kurtzberg of the Duke Center for Autism and Brain Development and the Carolinas Cord Blood Bank.
As the cord blood market has expanded to include a wide range of perinatal tissues, including umbilical cord tissue, placental blood and tissue, and amniotic fluid and tissue, the new frontier has become Longevity applications. Perinatal is a term describing the period right before and after birth. [Read more…]
RegMed Innovative Spikes on Heels of CAR-T, Gene Therapy, & Digital Pill Approvals
The regenerative medicine industry is a high-value, fast-growth market. With two CAR-T approvals, as well as the first gene therapy and digital pill approvals in the United States, we have had a lot of FDA “firsts.” The market gathered momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta), further “snowballing” the effect. [Read more…]
Best Cord Blood Banking Conferences
Cord blood conferences have been expanding in number and frequency over the past decade. Cord blood banking is the long-term storage and preservation of umbilical cord blood collected during the birth of a newborn. It is collected, because it is rich in hematopoietic stem cells (HSCs), a stem cell type that is widely used in transplant medicine and can be used to treat over 80 different conditions. The matrix of the umbilical cord, called Wharton’s Jelly, is also a rich source of mesenchymal stem cells (MSCs), a cell type that is now being explored in more than 800 clinical trials worldwide.
Each year, cord blood industry experts gather at these events to discuss trends, research progress, and clinical and technological advances.
Below, we highlight leading cord blood industry events, many of which BioInformant attends, sponsors, or helps to organize. [Read more…]
- « Previous Page
- 1
- …
- 234
- 235
- 236
- 237
- 238
- …
- 336
- Next Page »